| 前收市價 | 2.4300 |
| 開市 | 2.3800 |
| 買盤 | 1.6500 |
| 賣出價 | 3.0000 |
| 拍板 | 4.00 |
| 到期日 | 2024-05-17 |
| 今日波幅 | 2.3800 - 2.4300 |
| 合同範圍 | 無 |
| 成交量 | |
| 未平倉合約 | 264 |
Insider MonkeyBioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Q1 2024 Earnings Call Transcript
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Q1 2024 Earnings Call Transcript May 6, 2024 BioCryst Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-0.31 EPS, expectations were $-0.23. BCRX isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning, and welcome […]
Motley FoolWhy BioCryst Pharmaceuticals Vaulted Nearly 20% Higher on Monday
A better-than-expected first quarter and a goal of profitability and positive cash flow by the end of 2025 brought on a bit of a rally.
BenzingaBioCryst Pharmaceuticals 'Fantastic' Q1 Earnings Rides On Outstanding Orladeyo Performance
Monday, BioCryst Pharmaceuticals Inc (NASDAQ:BCRX) reported a first-quarter earnings loss of $(0.17) per share versus the consensus estimate loss of $(0.21) per share and $(0.28) reported a year ago. BioCryst Pharma reported sales of $92.8 million, beating the consensus of $85.61 million. The sales increased 34.9% Y/Y, primarily due to $88.9 million in Orladeyo’s net revenue in the first quarter of 2024, up 30% Y/Y. “We are off to a fantastic start to the year with outstanding Orladeyo revenue g
